Stock 0R1F BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Share Price London S.E.

Equities

0R1F

US1101221083

Pharmaceuticals

Market Closed - London S.E.
Other stock markets
 16:30:00 14/06/2024 BST 		5-day change 1st Jan Change
41.28 USD -2.70% Intraday chart for Bristol-Myers Squibb Company +0.40% -19.29%
06-14 Bristol Myers: FDA approval for treatment CF
06-13 Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors MT
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 46.09B 3,634B Sales 2025 * 46.06B 3,631B Capitalization 83.52B 6,584B
Net income 2024 * -5.41B -427B Net income 2025 * 10.22B 806B EV / Sales 2024 * 2.66 x
Net Debt 2024 * 39.03B 3,077B Net Debt 2025 * 31.68B 2,497B EV / Sales 2025 * 2.5 x
P/E ratio 2024 *
-15.7 x
P/E ratio 2025 *
7.79 x
Employees 34,100
Yield 2024 *
5.84%
Yield 2025 *
6.13%
Free-Float 69.27%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Bristol Myers: FDA approval for treatment CF
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors MT
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval DJ
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb MT
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb MT
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb CI
Transcript : Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial MT
Geron shares surge after U.S. FDA approves blood disorder drug RE
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers CI
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients MT
Bristol Myers: positive results in liver cancer CF
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial CI
Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company CI
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
More recommendations

Press releases Bristol-Myers Squibb Company

U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors BU
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma AQ
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial BU
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference BU
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : approbation de la FDA pour un traitement
Evotec erhält Forschungszahlung von 20 Mio USD von Myers Squibb
Bristol Myers : résultats positifs dans le cancer du foie
Bristol Myers : présente ses avancées en cancer du poumon
Bristol Myers : approbation de la FDA pour Breyanzi
More news

Quotes and Performance

1 day-2.70%
1 week+0.40%
Current month+0.57%
1 month-7.46%
3 months-21.31%
6 months-18.74%
Current year-19.29%
More quotes

Highs and lows

1 week
40.75
Extreme 40.7539
43.11
1 month
39.92
Extreme 39.92
44.30
Current year
39.92
Extreme 39.92
55.00
1 year
39.92
Extreme 39.92
66.37
3 years
39.92
Extreme 39.92
81.40
5 years
39.92
Extreme 39.92
81.40
10 years
39.92
Extreme 39.92
81.40
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 31/01/15
David Elkins DFI
 Director of Finance/CFO 55 19/11/19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19/11/19
Peter Arduini BRD
 Director/Board Member 59 31/03/16
Derica Rice BRD
 Director/Board Member 59 31/08/20
More insiders

Quotes

Date Price Change Volume
14/06/24 41.5 -0.18% 11,265
13/06/24 41.58 -2.57% 30,906
12/06/24 42.68 -0.16% 10,144
11/06/24 42.74 +1.14% 10,474
10/06/24 42.26 +2.78% 11,887

Delayed Quote London S.E., June 14, 2024 at 04:30 pm

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
26/07/2024 - Q2 2024 Earnings Release
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.2 USD
Average target price
53.19 USD
Spread / Average Target
+29.11%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.96% 630B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.15% 350B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.77% 328B
ABBVIE INC. Stock AbbVie Inc.
+8.79% 298B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.02% 246B
ROCHE HOLDING AG Stock Roche Holding AG
+1.27% 225B
NOVARTIS AG Stock Novartis AG
+11.95% 218B
AMGEN INC. Stock Amgen Inc.
+3.68% 160B
PFIZER, INC. Stock Pfizer, Inc.
-4.38% 156B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. 0R1F Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW